

Synthesis of CF₃-Containing 3,3'-Cyclopropyl Spirooxindoles by Sequential [3 + 2] Cycloaddition/Ring Contraction of Ylideneoxindoles with 2,2,2-Trifluorodiazooethane


Tian-Ren Li, Shu-Wen Duan, Wei Ding, Yi-Yin Liu, Jia-Rong Chen, Liang-Qiu Lu,* and Wen-Jing Xiao*

Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, 152 Luoyu Road, Wuhan, Hubei 430079, China

Collaborative Innovation Center of Chemical Science and Engineering, Tianjin 300072, China

S Supporting Information

ABSTRACT: A [3 + 2] cycloaddition/ring contraction sequence of ylideneoxindoles with in situ-generated 2,2,2-trifluorodiazooethane without the use of any transition-metal catalyst has been developed. The reaction provides efficient access to biologically important and synthetically useful CF₃-containing 3,3'-cyclopropyl spirooxindoles in high yield (74–99%) with high diastereoselectivity (>95:5 d.r.).



Spirocyclic oxindoles, especially 3,3'-cyclopropyl spirooxindoles, represent a ubiquitous class of biologically important compounds. They can be also widely found in various natural products and pharmaceuticals.^{1–3} For example, many compounds containing the 3,3'-cyclopropyl spirooxindole moiety exhibit interesting biological activities, and some have been identified as powerful HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) as well as kinase and arginine vasopressin inhibitors (Scheme 1).⁴ On the other hand, enriching the repertoire of fluorine-containing carbo- and heterocycles has attracted extensive research efforts from synthetic and medical chemists over the past decade because of the unique fluorine effect on the physicochemical properties of pharmaceuticals and drug candidates.⁵ In this context, the search for efficient and powerful methodologies for the construction of highly substituted and functionalized carbo- and heterocyclic rings bearing CF₃ moieties has recently become an attractive research topic, since the incorporation of CF₃ groups into drugs always leads to significant improvements in lipophilicity, binding selectivity, and metabolic stability compared with the parent molecules.⁶

Recently, the highly reactive compound 2,2,2-trifluorodiazooethane (CF₃CHN₂) has been identified as a robust C₁ unit for the synthesis of CF₃-containing cyclopropane derivatives.⁷ Notably, Carreira and co-workers have demonstrated that this type of reagent can be easily generated in situ from commercially available CF₃CH₂NH₂·HCl in the presence of NaNO₂.⁸ Accordingly, harsh reaction conditions and direct handling of toxic, gaseous, and explosive CF₃CHN₂ can be avoided by using this strategy. As a result, a wide range of transition-metal-promoted cyclopropanations of various terminal olefins and alkynes have been accomplished, providing efficient access to the corresponding structurally diverse CF₃-




containing small-ring molecules with high reaction efficiency (Scheme 2, eq 1). Other impressive work has come from the Mykhailiuk group, who reported the cycloaddition of in situ-generated CF₃CHN₂ with α -methylene aminocarboxylates to prepare 1-amino-2-(trifluoromethyl)cyclopropane-1-carboxylic esters, albeit with relatively low diastereoselectivity.⁹ Quite recently, the Ma group developed the Ag₂O-mediated [3 + 2] cycloaddition reaction of in situ-generated CF₃CHN₂ with terminal alkynes, which furnishes a diverse set of biologically important 3-(trifluoromethyl)pyrazoles in good yields (Scheme 2, eq 2).¹⁰ Despite the advances being made, trisubstituted electron-deficient alkenes still remain rarely exploited in cycloaddition reactions with the use of CF₃CHN₂ as a CF₃ synthon. As part of our ongoing research program on developing new cascade reactions to construct carbo- and heterocyclic systems,¹¹ we have developed a highly efficient sequential [3 + 2] cycloaddition/ring contraction reaction of CF₃CHN₂ with ylideneoxindoles under metal-free conditions. The reaction provides access to densely functionalized CF₃-containing 3,3'-cyclopropyl spirooxindoles in high yields and stereoselectivities (Scheme 2, eq 3).

Initially, ethyl (*E*)-2-(1-methyl-2-oxindolin-3-ylidene)-acetate (**1a**) was chosen as the model substrate to react with CF₃CHN₂, which was generated in situ from CF₃CH₂NH₂·HCl and NaNO₂ in DCM/H₂O at 0 °C. To our delight, the initial [3 + 2] cycloaddition occurred smoothly to give the corresponding cycloadduct **3a** in 87% isolated yield with excellent regioselectivity and diastereoselectivity (Table 1, entry 1). The structure of **3a** was unambiguously confirmed by single-crystal X-ray analysis.¹² Significantly, the subsequent ring

Received: January 6, 2014

Published: February 7, 2014

Scheme 1. Representative Therapeutic Agents Containing 3,3'-Cyclopropyl Spirooxindole Scaffolds


Scheme 2. Design of the [3 + 2] Cycloaddition/Ring Contraction Sequence for the Synthesis of CF₃-Containing 3,3'-Cyclopropyl SpirooxindolesTable 1. Optimization of the Reaction Conditions^a

entry	T (°C)	solvent	t (h)	yield of 3a (%) ^b	d.r. of 3a ^c	yield of 4a (%) ^b
1	0	DCM	72	87	>95:5	87
2	25	DCM	60	87	>95:5	n.d. ^d
3	40	DCM	48	81	>95:5	n.d.
5	25	CHCl ₃	36	92	>95:5	n.d.
6	25	DCE	48	83	>95:5	n.d.
7	25	toluene	36	90	>95:5	n.d.
8 ^e	25	toluene	36	n.d. ^e	>95:5	91
9 ^{e,f}	25	toluene	96	n.d. ^e	>95:5	84

^aReaction conditions: **1a** (0.2 mmol, 1.0 equiv), CF₃CH₂NH₂·HCl (5 equiv), NaNO₂ (6 equiv), solvent (3.0 mL), H₂O (0.2 mL). ^bIsolated yields based on **1a**. ^cDetermined by ¹H NMR analysis. ^dn.d. = not determined. ^eThe reaction mixture was directly warmed to reflux for 1 h upon complete consumption of **1a**. ^f2/NaNO₂ (0.6/0.72 mmol, 3/3.6 equiv) were used.

contraction reaction of **3a** also worked very well in refluxing toluene to afford the final CF₃-substituted 3,3'-cyclopropyl spirooxindole **4a** in 87% overall yield with excellent diastereoselectivity. These results encouraged us to investigate other reaction parameters to further improve the reaction efficiency. It was found that the reaction at room temperature gave a comparable yield of **3a** with reduced reaction time, while elevating the temperature to 40 °C resulted in somewhat inferior results, probably because of the instability and volatility

of CF₃CHN₂ (Table 1, entry 2 vs entry 3). A brief screen of reaction media showed that toluene was the best solvent of choice (Table 1, entry 7). Notably, the sequential [3 + 2] cycloaddition/ring contraction reaction could be carried out in a one-pot fashion in toluene, affording the desired product **4a** in 91% overall yield (Table 1, entry 8). The reaction with reduced amounts of CF₃CH₂NH₂·HCl and NaNO₂ led to a slight drop in the overall yield (Table 1, entry 9).¹²


Scheme 3. Scope of the [3 + 2] Cycloaddition/Ring Contraction Sequence^a

^aReaction conditions: see entry 8 of Table 1. Yields of isolated products are shown; all of the d.r. values were determined by ^1H NMR analysis.

With the optimized conditions in hand, we then investigated the substrate scope of this tandem reaction. As shown in Scheme 3, a wide range of 3-ylideneoxindoles were found to be suitable for the reaction. Both electron-donating groups (e.g., Me and MeO) and electron-withdrawing groups (e.g., F, Br, NO_2 , CF_3O , Cl, and CF_3) were well-tolerated under the reaction conditions, and the corresponding CF_3 -containing 3,3'-cyclopropyl spirooxindoles **4a–m** were obtained in 79–99% yield with >95:5 dr. Importantly, the above-mentioned halo-substituted products allowed for further transformations

through transition-metal-catalyzed cross-coupling reactions. Notably, the products bearing CF_3O , CF_3 , and F groups on the aromatic ring (**4g**, 88% yield; **4l**, 79% yield; **4m**, 85% yield; Scheme 3) should also be of significant interest to medicinal chemists because of the potential effect of fluorine on the physicochemical properties of these molecules.

Moreover, the effects of varying the N-protecting group and the ester moiety of the 3-ylideneoxindole were examined. As shown in Scheme 3, 3-ylideneoxindoles with N-protecting groups such as Ph (**1o**), Bn (**1p**), allyl (**1q**) or without a

Scheme 4. Sequential [3 + 2] Cycloaddition/1,3-H Shift Reaction for the Synthesis of CF₃-Containing Spiropyrzoline Oxindole 5

protecting group could participate in this reaction very well, providing the corresponding products **4n–q** in 74–92% yield. Variation of the ester moiety (e.g., Me, Et, or *t*Bu) had less effect on both the reaction efficiency and stereoselectivity. Remarkably, the reaction was also successfully extended to 3-ylideneoxindoles with (hetero)aromatic carbonyl substituents. For example, the reactions with phenyl- and 2-thiophene-substituted carbonyl groups worked very well, producing **4t** and **4u** in 99% and 98% yield, respectively. Perhaps more importantly, spirooxindole **4v**, an analogue of an HIV-1 NNRTI, was successfully synthesized in one step from ethyl (*E*)-2-(5-bromo-2-oxindolin-3-ylidene)acetate by this methodology, which further highlights the synthetic potential of this transformation.⁴ All of these products were fully characterized by ¹H NMR, ¹³C NMR, and HRMS analysis. The structure and stereochemistry of product **4c** were also unambiguously confirmed by single-crystal X-ray analysis.¹²

Interestingly, an alternative sequential [3 + 2] cycloaddition/1,3-H shift reaction was also disclosed during optimization of the reaction conditions. As shown in Scheme 4, in the case of ethyl (*E*)-2-(1,5-dimethyl-2-oxindolin-3-ylidene)acetate (**1b**), the reaction formed CF₃-substituted spiropyrzoline oxindole **5** with high diastereoselectivity when DABCO was used as the base (91% yield, >95:5 d.r.; Scheme 4). It is noteworthy that this process provides a complementary method to synthesize compounds bearing both oxindole and pyrazoline skeletons.¹³

In summary, we have developed the first example of a sequential [3 + 2] cycloaddition/ring contraction reaction of 3-ylideneoxindoles with in situ-generated CF₃CHN₂ under transition-metal-free conditions. This method provides a straightforward approach to highly substituted and functionalized CF₃-containing 3,3'-cyclopropyl spirooxindole derivatives in excellent yields with great diastereoselectivities. Significantly, a CF₃-substituted analogue of an HIV-1 NNRTI can be synthesized in one step by this methodology. Moreover, a sequential [3 + 2] cycloaddition/1,3-H shift reaction promoted by DABCO was also disclosed, providing a new access to CF₃-containing spiropyrzoline oxindoles.

EXPERIMENTAL SECTION

General Considerations. Unless otherwise noted, materials were purchased from commercial suppliers and used without further purification. All of the solvents were treated according to known methods.

General Procedure for the Synthesis of 3-Ylideneoxindoles. To a stirred solution of ethyl 2-(triphenylphosphoranylidene)acetate (22 mmol, 1.1 equiv) in anhydrous THF (50 mL) was added *N*-methylindoline-2,3-dione (20 mmol, 1.0 equiv) at 0 °C. The mixture was stirred at the same temperature until the reaction was complete, as monitored by TLC analysis. The crude product was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate 5:1). Compound **1a** was obtained as a red solid (1.74 g, 86% yield). The

other 3-ylideneoxindoles were prepared according to the above procedure using the corresponding acetates and diones.

General Procedure for the Sequential [3 + 2] Cycloaddition/Ring Contraction Reaction of Alkylenyloxindoles with in Situ-Generated CF₃CHN₂. CF₃CH₂NH₂·HCl (135.5 mg, 1.0 mmol, 5 equiv), NaNO₂ (83 mg, 1.2 mmol, 6 equiv), and H₂O (0.2 mL) were stirred in 3.0 mL of toluene at 0 °C for 1 h in a 10 mL Schlenk tube under Ar. Then alkylenyloxindole **1** (0.20 mmol) was added, and the reaction mixture was stirred at room temperature for 36 h. The mixture was then heated to reflux for 1.5 h with vigorous stirring. Upon completion of the reaction (as monitored by TLC), the reaction mixture was cooled to room temperature and then directly subjected to column chromatography to afford the desired product **4**.

General Procedure for the Sequential [3 + 2] Cycloaddition/1,3-H Shift Reaction for the Synthesis of CF₃-Containing Spiropyrzoline Oxindoles with in Situ-Generated CF₃CHN₂. CF₃CH₂NH₂·HCl (135.5 mg, 1.0 mmol, 5 equiv), NaNO₂ (83 mg, 1.2 mmol, 6 equiv), and H₂O (0.2 mL) were stirred in 3.0 mL of DCM at 0 °C for 1 h in a 10 mL Schlenk tube under Ar. Then DABCO (11.2 mg, 0.1 mmol) (0.5 equiv) was added, followed by alkylenyloxindole **1** (0.20 mmol), and the reaction mixture was stirred at room temperature for 48 h. Upon completion of the reaction (as monitored by TLC), the reaction mixture was cooled to room temperature and then directly subjected to column chromatography to afford the desired product **5**.

Ethyl 1-Methyl-2-oxo-5'-(trifluoromethyl)-4',5'-dihydrospiro[indoline-3,3'-pyrazole]-4'-carboxylate (3a). 48 h, white solid (59.4 mg, 87% yield), mp 120.6 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.43 (t, *J* = 7.5 Hz, 1H), 7.04 (t, *J* = 7.7 Hz, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.77 (d, *J* = 7.5 Hz, 1H), 5.96–5.89 (m, 1H), 3.93–3.72 (m, 2H), 3.64 (d, *J* = 9.1 Hz, 1H), 3.38 (s, 3H), 0.68 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 170.2, 166.8, 144.4, 131.6, 124.5, 123.2, 123.0 (q, *J* = 277 Hz), 120.6, 108.9, 99.4, 91.8 (q, *J* = 28.7 Hz), 61.9, 45.0, 26.9, 13.1. ¹⁹F NMR (376 MHz, CDCl₃): δ –71.06. MS (EI): *m/z* 341.03 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₄F₃N₃O₃ [M + Na]⁺: calcd 364.0879, found 364.0885.

Ethyl 1'-Methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4a). 48 h, colorless oil (56.9 mg, 91% yield), d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.37 (t, *J* = 7.7 Hz, 1H), 7.33 (d, *J* = 7.7 Hz, 1H), 7.08 (t, *J* = 7.6 Hz, 1H), 6.94 (d, *J* = 7.7 Hz, 1H), 4.25–4.13 (m, 2H), 3.38 (d, *J* = 7.7 Hz, 1H), 3.33 (s, 3H), 3.20–3.14 (m, 1H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 170.1, 166.2, 144.0, 128.9, 123.5, 123.3 (q, *J* = 274 Hz), 122.5, 122.4, 108.3, 62.0, 36.2, 35.3 (q, *J* = 41.0 Hz), 34.9 (d, *J* = 3 Hz), 26.8, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.17. MS (EI): *m/z* 313.23 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₄F₃N₃O₃ [M + H]⁺: calcd 314.0999, found 314.1000.

Ethyl 1',5'-Dimethyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4b). 48 h, white solid (57.6 mg, 88% yield), mp 107.9 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.14 (d, *J* = 7.9 Hz, 1H), 7.12 (s, 1H), 6.80 (d, *J* = 7.9 Hz, 1H), 4.24–4.10 (m, 2H), 3.34 (d, *J* = 7.7 Hz, 1H), 3.28 (s, 3H), 3.14–3.09 (m, 1H), 2.33 (s, 3H), 1.23 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 170.0, 166.2, 141.7, 132.1, 129.1, 123.5, 123.4 (q, *J* = 273 Hz), 123.1, 108.1, 62.0, 36.2, 35.2 (q, *J* = 40.7 Hz), 34.8, 26.7, 21.1, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.29. MS (EI): *m/z* 327.27 (M⁺). HRMS (ESI-TOF) for C₁₆H₁₆F₃N₃O₃ [M + H]⁺: calcd 328.1155, found 328.1155.

Ethyl 5'-Methoxy-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4c). 48 h, yellow solid (55.6 mg, 81% yield), mp 90.9 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 6.96 (d, J = 2.4 Hz, 1H), 6.87 (dd, J = 8.5 Hz, 2.5 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 4.23–4.11 (m, 2H), 3.78 (s, 3H), 3.35 (d, J = 7.8 Hz, 1H), 3.27 (s, 3H), 3.13–3.08 (m, 1H), 1.24 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 166.1, 155.8, 137.5, 124.6, 123.3 (q, J = 273 Hz), 113.5, 109.7, 108.7, 62.1, 55.7, 36.4, 35.4 (q, J = 41.0 Hz), 34.8, 26.8, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.28. MS (EI): m/z 344.0 (M⁺). HRMS (ESI-TOF) for C₁₆H₁₆F₃NO₄ [M + H]⁺: calcd 344.1104, found 344.1107.

Ethyl 5'-Fluoro-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4d). 36 h, yellow solid (57.7 mg, 87% yield), mp 87.4 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.13 (dd, J = 8.6 Hz, 2.6 Hz, 1H), 7.08–7.02 (m, 1H), 6.84 (dd, J = 8.6 Hz, 4.2 Hz, 1H), 4.27–4.13 (m, 2H), 3.37 (d, J = 7.8 Hz, 1H), 3.29 (s, 3H), 3.15–3.08 (m, 1H), 1.25 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 166.0, 158.9 (d, J = 239 Hz), 140.1 (d, J = 1 Hz), 125.0 (d, J = 10 Hz), 123.2 (q, J = 273 Hz), 115.1 (d, J = 23 Hz), 111.0 (d, J = 27 Hz), 108.8 (d, J = 8 Hz), 62.3, 36.3, 35.7 (q, J = 41.0 Hz), 34.9 (d, J = 3 Hz), 26.9, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.35, –119.99. MS (EI): m/z 331.26 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃F₄NO₃ [M + H]⁺: calcd 332.0904, found 332.0893.

Ethyl 5'-Bromo-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4e). 36 h, white solid (71.4 mg, 91% yield), mp 90.0 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.47 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.0 Hz, 1H), 4.26–4.15 (m, 2H), 3.36 (d, J = 7.8 Hz, 1H), 3.28 (s, 3H), 3.15–3.10 (m, 1H), 1.26 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.5, 165.9, 143.1, 131.7, 125.7, 125.4, 123.1 (q, J = 274 Hz), 115.1, 109.7, 62.3, 35.8, 35.6 (q, J = 39.7 Hz), 35.0, 26.8, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –63.01. MS (EI): m/z 391.21 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃BrF₃NO₃ [M + H]⁺: calcd 392.0104, found 392.0090.

Ethyl 1'-Methyl-5'-nitro-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4f). 36 h, yellow solid (59.4 mg, 83% yield), mp 143.1 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 8.33 (d, J = 8.6 Hz, 1H), 8.28 (s, 1H), 7.01 (d, J = 8.6 Hz, 1H), 4.28–4.17 (m, 2H), 3.42 (d, J = 7.9 Hz, 1H), 3.38 (s, 3H), 3.31–3.26 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 170.2, 165.6, 149.4, 143.3, 125.8, 124.2, 122.9 (q, J = 275 Hz), 118.8, 108.0, 62.6, 35.9 (q, J = 41 Hz), 35.6 (d, J = 2 Hz), 35.4 (d, J = 2 Hz), 27.3, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.54. MS (EI): m/z 359.15 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃F₃N₂O₅ [M + H]⁺: calcd 359.0849, found 359.0856.

Ethyl 1'-Methyl-2'-oxo-5'-(trifluoromethoxy)-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4g). 36 h, white solid (70.0 mg, 88% yield), mp 69.2 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.27 (s, 1H), 7.23 (d, J = 9.0 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 4.27–4.11 (m, 2H), 3.38 (d, J = 7.7 Hz, 1H), 3.31 (s, 3H), 3.20–3.12 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 165.9, 144.5, 142.8, 124.9, 123.1 (q, J = 274 Hz), 122.9 (q, J = 256 Hz), 122.1, 116.9, 108.7, 62.4, 36.0 (d, J = 2 Hz), 35.7 (q, J = 41 Hz), 35.1 (d, J = 3 Hz), 26.9, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.31, –58.83. MS (EI): m/z 398.0 (M⁺). HRMS (ESI-TOF) for C₁₆H₁₃F₆NO₄ [M + H]⁺: calcd 398.0822, found 398.0826.

Ethyl 4'-Bromo-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4h). 48 h, yellow solid (75.3 mg, 96% yield), mp 107.2 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.23 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 4.44 (d, J = 8.4 Hz, 1H), 4.29–4.22 (m, 2H), 3.25 (s, 3H), 3.06–3.01 (m, 1H), 1.31 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 171.4, 165.3, 146.6, 129.9, 128.0, 123.8 (q, J = 273 Hz), 120.4, 118.1, 107.9, 62.0, 37.7, 36.9 (q, J = 41.3 Hz), 29.0, 26.9, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –56.99. MS (EI): m/z 391.1 (M⁺), 393.1 ([M + 2]⁺). HRMS (ESI-TOF) for C₁₅H₁₃BrF₃NO₃ [M + H]⁺: calcd 392.0104, found 392.0095.

Ethyl 4'-Chloro-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4i). 48 h, yellow solid (69.0 mg, 99% yield), mp 88.6 °C, d.r. >95:5. ¹H NMR (400 MHz,

CDCl₃): δ 7.28 (t, J = 8.1 Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 4.29–4.21 (m, 3H), 3.26 (s, 3H), 3.09–3.04 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 171.2, 165.2, 146.3, 130.0, 129.7, 124.5, 123.7 (q, J = 272 Hz), 118.9, 107.3, 61.9, 36.8, 36.5 (q, J = 41.0), 29.2, 26.9, 13.9. ¹⁹F NMR (376 MHz, CDCl₃): δ –57.71. MS (EI): m/z 347.25 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃ClF₃NO₃ [M + H]⁺: calcd 348.0609, found 348.0608.

Ethyl 6'-Bromo-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4j). 36 h, white solid (71.5 mg, 91% yield), mp 129.5 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.27 (d, J = 2.6 Hz, 1H), 7.18 (s, 2H), 7.06 (s, 1H), 4.23–4.10 (m, 2H), 3.34 (d, J = 7.8 Hz, 1H), 3.28 (s, 3H), 3.14–3.10 (m, 1H), 1.24 (t, J = 6.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 166.0, 145.3, 125.3, 123.8, 123.1 (q, J = 274 Hz), 122.6, 122.3, 111.8, 62.2, 35.9, 35.3 (q, J = 40.7 Hz), 34.9, 26.8, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.36. MS (EI): m/z 391.24 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃BrF₃NO₃ [M + H]⁺: calcd 392.0104, found 392.0094.

Ethyl 6'-Chloro-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4k). 48 h, yellowish solid (64.8 mg, 93% yield), mp 102.5 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.22 (d, J = 7.8 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 6.89 (d, J = 7.2 Hz, 1H), 4.45 (d, J = 8.4 Hz, 1H), 4.30–4.21 (m, 2H), 3.25 (s, 3H), 3.06–3.01 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 171.4, 165.2, 146.6, 129.9, 128.0, 123.8 (q, J = 273 Hz), 120.4, 118.1, 107.9, 62.0, 37.6, 36.8 (q, J = 41 Hz), 28.9, 26.8, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –57.03. MS (EI): m/z 348.0 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃ClF₃NO₃ [M + H]⁺: calcd 348.0609, found 348.0599.

Ethyl 1'-Methyl-2'-oxo-3,7'-bis(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4l). 36 h, red oil (60.3 mg, 79% yield), d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.64 (s, 1H), 7.50 (s, 1H), 7.12 (s, 1H), 4.23–4.13 (m, 2H), 3.51 (s, 3H), 3.40 (s, 1H), 3.19 (s, 1H), 1.24 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 171.0, 165.8, 142.0, 126.8 (q, J = 5.7 Hz), 125.8, 125.7, 123.4 (q, J = 270 Hz), 123.1 (q, J = 274 Hz), 121.8, 112.9 (q, J = 33 Hz), 62.4, 36.1, 35.9 (q, J = 41 Hz), 35.0, 29.6 (q, J = 6.3 Hz), 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –53.64, –58.47. MS (EI): m/z 382.0 (M⁺). HRMS (ESI-TOF) for C₁₆H₁₃F₆NO₃ [M + H]⁺: calcd 382.0872, found 382.0879.

Ethyl 7'-Fluoro-1'-methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4m). 36 h, white solid (56.4 mg, 85% yield), mp 89.0 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.09 (s, 1H), 7.06 (d, J = 12.4 Hz, 1H), 7.03–6.92 (m, 1H), 4.26–4.10 (m, 2H), 3.51 (s, 3H), 3.36 (d, J = 7.8 Hz, 1H), 3.16–3.09 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 165.9, 147.7 (d, J = 242 Hz), 130.8 (d, J = 9 Hz), 126.2 (d, J = 4 Hz), 123.2 (q, J = 273 Hz), 123.0 (d, J = 6 Hz), 118.3 (q, J = 3 Hz), 116.9 (d, J = 19 Hz), 62.2, 36.2, 35.8 (q, J = 41 Hz), 35.4, 29.4, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.35, –136.56. MS (EI): m/z 331.28 (M⁺). HRMS (ESI-TOF) for C₁₅H₁₃F₄NO₃ [M + H]⁺: calcd 332.0904, found 332.0891.

Ethyl 2'-Oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4n). 48 h, white solid (49.2 mg, 82% yield), mp 153.1 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 8.89 (s, 1H), 7.28 (t, J = 7.3 Hz, 2H), 7.03 (t, J = 7.7 Hz, 1H), 6.97 (d, J = 7.9 Hz, 1H), 4.26–4.11 (m, 2H), 3.36 (d, J = 7.8 Hz, 1H), 3.18–3.13 (m, 1H), 1.24 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 173.0, 166.1, 141.5, 128.9, 124.0, 123.4 (q, J = 273 Hz), 122.6, 122.5, 110.5, 62.2, 36.7, 35.6 (q, J = 41.0 Hz), 35.0, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ –58.21. MS (EI): m/z 300.1 (M⁺). HRMS (ESI-TOF) for C₁₄H₁₂F₃NO₃ [M + H]⁺: calcd 300.0842, found 300.0846.

Ethyl 2'-Oxo-1'-phenyl-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4o). 36 h, white solid (69.1 mg, 92% yield), mp 90.9 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 7.53 (t, J = 7.5 Hz, 2H), 7.45–7.39 (m, 4H), 7.26 (t, J = 7.5 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 4.30–4.12 (m, 2H), 3.45 (d, J = 7.7 Hz, 1H), 3.25–3.18 (m, 1H), 1.26 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.6, 166.2, 144.0, 134.0, 129.6, 128.8, 128.3, 126.5, 123.4, 123.3 (q, J = 274 Hz), 123.0, 122.8, 109.7, 62.2, 36.4 (d, J = 2 Hz), 36.0 (q, J = 41.3 Hz), 35.3 (d, J = 3 Hz), 14.0. ¹⁹F NMR (376

MHz, CDCl₃): δ -58.17. MS (EI): m/z 376.1 (M⁺). HRMS (ESI-TOF) for C₂₀H₁₆F₃NO₃ [M + H]⁺: calcd 376.1155, found 376.1158.

Ethyl 1'-Benzyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4p). 36 h, white solid (66.3 mg, 85% yield), mp 108.2 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.37–7.24 (m, 7H), 7.22 (t, J = 7.0 Hz, 1H), 7.01 (t, J = 7.2 Hz, 1H), 6.80 (d, J = 7.7 Hz, 1H), 5.11 (d, J = 15.6 Hz, 1H), 4.87 (d, J = 15.6 Hz, 1H), 4.26–4.11 (m, 2H), 3.46–3.43 (m, 1H), 3.19–3.17 (m, 1H), 1.25 (t, J = 8.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 170.4, 166.2, 143.2, 135.4, 128.8, 128.8, 127.7, 127.2, 123.6, 123.4 (q, J = 274 Hz), 122.6, 122.5, 109.3, 62.1, 44.3, 36.2 (d, J = 3 Hz), 35.7 (q, J = 40.7 Hz), 35.0 (d, J = 3 Hz), 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.19. MS (EI): m/z 390.1 (M⁺). HRMS (ESI-TOF) for C₂₁H₁₈F₃NO₃ [M + H]⁺: calcd 390.1312, found 390.1317.

Ethyl 1'-Allyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4q). 48 h, purple solid (50.1 mg, 74% yield), mp 89.9 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.33–7.29 (m, 2H), 7.04 (t, J = 7.6 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 5.89–5.83 (m, 1H), 5.25 (s, 1H), 5.23 (d, J = 4.7 Hz, 1H), 4.48–4.36 (m, 2H), 4.25–4.10 (m, 2H), 3.38 (d, J = 7.7 Hz, 1H), 3.17–3.13 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 166.2, 143.2, 131.0, 128.8, 123.5, 123.3 (q, J = 274 Hz), 122.5, 122.5, 117.8, 109.2, 62.1, 42.9, 36.1, 35.6 (q, J = 40.7 Hz), 34.9, 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.37. MS (EI): m/z 340.1 (M⁺). HRMS (ESI-TOF) for C₁₇H₁₆F₃NO₃ [M + H]⁺: calcd 340.1155, found 340.1165.

Methyl 1'-Methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4r). 36 h, purple solid (52.6 mg, 88% yield), mp 94.6 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.35 (t, J = 7.7 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 7.06 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 3.72 (s, 3H), 3.37 (d, J = 7.7 Hz, 1H), 3.30 (s, 3H), 3.18–3.13 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 170.0, 166.7, 144.1, 128.9, 123.4, 123.3 (q, J = 273 Hz), 122.6, 122.4, 108.4, 52.8, 36.3 (d, J = 3 Hz), 35.3 (q, J = 40.7 Hz), 34.7 (d, J = 3 Hz), 26.8. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.43. MS (EI): m/z 300.0 (M⁺). HRMS (ESI-TOF) for C₁₄H₁₂F₃NO₃ [M + H]⁺: calcd 300.0842, found 300.0849.

tert-Butyl 1'-Methyl-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4s). 48 h, white solid (62.8 mg, 92% yield), mp 101.2 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.33 (t, J = 7.7 Hz, 1H), 7.27 (d, J = 10.0 Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 3.31 (s, 3H), 3.28 (s, 1H), 3.10–3.05 (m, 1H), 1.39 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 170.4, 165.0, 144.0, 128.7, 123.6, 123.5 (q, J = 274 Hz), 122.4, 122.3, 108.3, 83.1, 35.9, 35.1 (q, J = 40.7 Hz), 27.9, 26.8. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.26. MS (EI): m/z 342.2 (M⁺). HRMS (ESI-TOF) for C₁₇H₁₈F₃NO₃ [M + H]⁺: calcd 342.1312, found 342.1313.

2-Benzoyl-1'-methyl-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (4t). 48 h, orange solid (68.7 mg, 99% yield), mp 129.0 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.91 (d, J = 7.7 Hz, 2H), 7.56 (t, J = 6.6 Hz, 1H), 7.43 (t, J = 6.9 Hz, 2H), 7.27 (t, J = 6.7 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 6.98 (t, J = 7.3 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 4.28 (d, J = 7.5 Hz, 1H), 3.51–3.46 (m, 1H), 3.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 190.1, 170.3, 143.7, 135.9, 134.1, 128.8, 128.7, 128.5, 123.7 (q, J = 273 Hz), 123.3, 122.7, 122.1, 108.3, 38.3, 37.9, 34.9 (q, J = 40.3 Hz), 26.9. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.27. MS (EI): m/z 346.0 (M⁺). HRMS (ESI-TOF) for C₁₉H₁₄F₃NO₂ [M + H]⁺: calcd 346.1049, found 346.1058.

1'-Methyl-2-(thiophene-2-carbonyl)-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (4u). 48 h, yellow solid (68.5 mg, 98% yield), mp 137.3 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.78 (s, 1H), 7.68 (d, J = 3.9 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.10 (s, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 4.17 (d, J = 7.6 Hz, 1H), 3.47–3.42 (m, 1H), 3.31 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 182.5, 170.2, 143.8, 143.3, 135.6, 133.6, 128.8, 128.5, 123.6 (q, J = 273 Hz), 123.3, 122.7, 122.5, 108.3, 38.7, 38.1, 34.9 (q, J = 40.3 Hz), 26.8. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.25. MS (EI): m/z 352.1 (M⁺). HRMS (ESI-TOF) for C₁₇H₁₂F₃NO₂S [M + H]⁺: calcd 352.0614, found 352.0612.

Ethyl 5'-Bromo-2'-oxo-3-(trifluoromethyl)spiro[cyclopropane-1,3'-indoline]-2-carboxylate (4v). 36 h, white solid (61.7 mg, 82% yield), mp 187.8 °C, d.r. >95:5. ¹H NMR (400 MHz, CDCl₃): δ 9.90 (s, 1H), 7.45 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 4.26–4.20 (m, 2H), 3.35 (d, J = 7.2 Hz, 1H), 3.21–3.12 (m, 1H), 1.27 (t, J = 6.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 172.7, 165.8, 140.5, 131.8, 126.0, 125.9, 123.1 (q, J = 273 Hz), 115.2, 112.0, 62.5, 36.5, 35.9 (q, J = 41.0 Hz), 35.2 (d, J = 2 Hz), 14.0. ¹⁹F NMR (376 MHz, CDCl₃): δ -58.33. MS (EI): m/z 377.32 (M⁺). HRMS (ESI-TOF) for C₁₄H₁₁BrF₃NO₃ [M + H]⁺: calcd 377.9947, found 377.9955.

Ethyl 1,5-Dimethyl-2-oxo-5'-(trifluoromethyl)-2',4'-dihydrospiro[indoline-3,3'-pyrazole]-4'-carboxylate (5). 72 h, white solid (63.0 mg, 91% yield), mp 135.0 °C, d.r. >95:5. ¹H NMR (600 MHz, CDCl₃): δ 7.17 (d, J = 7.9 Hz, 1H), 7.10 (s, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.17 (s, 1H), 4.58 (s, 1H), 3.91–3.81 (m, 2H), 3.24 (s, 3H), 2.31 (s, 3H), 0.88 (t, J = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 174.6, 165.1, 140.9, 137.2 (q, J = 38 Hz), 133.1, 131.3, 125.4, 125.1, 119.8 (q, J = 269 Hz), 108.4, 73.1, 61.6, 58.6 (d, J = 3.0 Hz), 26.7, 20.8, 13.4. ¹⁹F NMR (376 MHz, CDCl₃): δ -63.45. MS (EI): m/z 355.12 (M⁺). HRMS (ESI-TOF) for C₁₆H₁₆F₃N₃O₃ [M + Na]⁺: calcd 378.1036, found 378.1036.

■ ASSOCIATED CONTENT

Supporting Information

Full experimental details, spectroscopic data for **4** and **5**, and CIF files for **3a** and **4c**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: wxiao@mail.ccnu.edu.cn.

*E-mail: luliangqiu@mail.ccnu.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are grateful to the National Natural Science Foundation of China (21232003, 21202053, and 21272087) and the National Basic Research Program of China (2011CB808603) for support of this research.

■ REFERENCES

- (1) For reviews of spirocyclic oxindoles, see: (a) Singh, G. S.; Desta, Z. Y. *Chem. Rev.* **2012**, *112*, 6104. (b) Zhou, F.; Liu, Y.; Zhou, J. *Adv. Synth. Catal.* **2010**, *352*, 1381. (c) Trost, B.; Brennan, M. *Synthesis* **2009**, 3003. (d) Galliford, C. V.; Scheidt, K. A. *Angew. Chem., Int. Ed.* **2007**, *46*, 8748.
- (2) (a) Bagley, J. R.; Thomas, S. A.; Rudo, F. G.; Spencer, H. K.; Doorley, B. M.; Ossipov, M. H.; Jerussi, T. P.; Benvenga, M. J.; Spaulding, T. J. *Med. Chem.* **1991**, *34*, 827. (b) Schwartz, R. E.; Hirsch, C. F.; Springer, J. P.; Pettibone, D. J.; Zink, D. L. *J. Org. Chem.* **1987**, *52*, 3704. (c) Robertson, D. W.; Krushinski, J. H.; Pollock, G. D.; Wilson, H.; Kauffman, R. F.; Hayes, J. S. *J. Med. Chem.* **1987**, *30*, 824.
- (3) (a) Helan, V.; Mills, A.; Drewry, D.; Grant, D. J. *Org. Chem.* **2010**, *75*, 6693. (b) Marti, C.; Carreira, E. M. *J. Am. Chem. Soc.* **2005**, *127*, 11505. (c) Alper, P. B.; Meyers, C.; Lerchner, A.; Siegel, D. R.; Carreira, E. M. *Angew. Chem., Int. Ed.* **1999**, *38*, 3186.
- (4) (a) He, Y.; Jiang, T.; Kuhen, K. L.; Ellis, D. A.; Wu, B.; Wu, T. Y.; Bursulaya, B. Patent WO 2004037247, 2004. (b) Ellis, D.; Kuhen, K. L.; Anacletio, B.; Wu, B.; Wolff, K.; Yin, H.; Bursulaya, B.; Caldwell, J.; Karanewsky, D.; He, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4246. (c) Jiang, T.; Kuhen, K. L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Wu, T. Y.; He, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2105. (d) Jiang, T.; Kuhen, K. L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Tuntland, T.; Zhang, K.; Karanewsky, D.; He, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2109. (e) He, Y.; Jiang, T.;

Kuhen, K. L.; Ellis, D. A.; Wu, B.; Wu, T. Y.; Bursulaya, B. U.S. Patent 7,205,328, 2007. (f) Dou, X.; Lu, Y. *Chem.—Eur. J.* **2012**, *18*, 8315.

(5) For recent reviews, see: (a) Lectard, S.; Hamashima, Y.; Sodeoka, M. *Adv. Synth. Catal.* **2010**, *352*, 2708. (b) Hu, J.; Zhang, W.; Wang, F. *Chem. Commun.* **2009**, 7465. (c) Ma, J.; Cahard, D. *Chem. Rev.* **2008**, *108*, PR1. (d) Kirk, K. L. *Org. Process Res. Dev.* **2008**, *12*, 305. (e) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320. (f) Petrov, V. A. In *Fluorinated Heterocyclic Compounds: Synthesis, Chemistry, and Applications*; John Wiley & Sons: Hoboken, NJ, 2009.

(6) For selected reviews, see: (a) Chen, P.; Liu, G. *Synthesis* **2013**, *45*, 2919. (b) Tomashenko, O. A.; Grushin, V. V. *Chem. Rev.* **2011**, *111*, 4475. (c) Nie, J.; Guo, H.; Cahard, D.; Ma, J. *Chem. Rev.* **2011**, *111*, 455. For recent examples, see: (d) Zeng, Y.; Zhang, L.; Zhao, Y.; Ni, C.; Zhao, J.; Hu, J. *J. Am. Chem. Soc.* **2013**, *135*, 2955. (e) He, Z.; Zhang, R.; Hu, M.; Li, L.; Ni, C.; Hu, J. *Chem. Sci.* **2013**, *4*, 3478. (f) Mu, X.; Wu, T.; Wang, H. Y.; Guo, Y. L.; Liu, G. *J. Am. Chem. Soc.* **2012**, *134*, 878. (g) Chen, C.; Chu, L.; Qing, F. *J. Am. Chem. Soc.* **2012**, *134*, 12454. (h) Zhu, R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2012**, *134*, 12462. (i) Mu, X.; Chen, S.; Zhen, X.; Liu, G. *Chem.—Eur. J.* **2011**, *17*, 6039. (j) Chu, L.; Qing, F.-L. *J. Am. Chem. Soc.* **2012**, *134*, 1298. (k) Nagib, D. A.; MacMillan, D. W. C. *Nature* **2011**, *480*, 224. (l) Cho, E. J.; Senecal, T. D.; Kinzel, T.; Zhang, Y.; Watson, D. A.; Buchwald, S. L. *Science* **2010**, *328*, 1679.

(7) For a recent review of the chemistry of trifluoromethyl-substituted cyclopropanes, see: Grygorenko, O. O.; Artamonov, O. S.; Komarov, I. V.; Mykhailiuk, P. K. *Tetrahedron* **2011**, *67*, 803.

(8) (a) Kunzi, S. A.; Morandi, B.; Carreira, E. M. *Org. Lett.* **2012**, *14*, 1900. (b) Morandi, B.; Mariampillai, B.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2011**, *50*, 1101. (c) Morandi, B.; Cheang, J.; Carreira, E. M. *Org. Lett.* **2011**, *13*, 3080. (d) Morandi, B.; Carreira, E. M. *Org. Lett.* **2011**, *13*, 5984. (e) Morandi, B.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2011**, *50*, 9085. (f) Morandi, B.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 938. (g) Morandi, B.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 4294.

(9) (a) Artamonov, O.; Slobodyanyuk, E.; Shishkin, O.; Komarov, I.; Mykhailiuk, P. *Synthesis* **2013**, *45*, 225. (b) Artamonov, O.; Mykhailiuk, P.; Voievoda, N.; Volochnyuk, D.; Komarov, I. *Synthesis* **2010**, 443.

(10) (a) Li, F.; Nie, J.; Sun, L.; Zheng, Y.; Ma, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 6255. (b) Liu, C.-B.; Meng, W.; Li, F.; Wang, S.; Nie, J.; Ma, J. *Angew. Chem., Int. Ed.* **2012**, *51*, 6227.

(11) For a recent account, see: (a) Lu, L.-Q.; Chen, J.-R.; Xiao, W.-J. *Acc. Chem. Res.* **2012**, *45*, 1278. For selected recent examples, see: (b) Duan, S.-W.; Li, Y.; Liu, Y.-Y.; Zou, Y.-Q.; Shi, D.-Q.; Xiao, W.-J. *Chem. Commun.* **2012**, 48, 5160. (c) Yang, Q.-Q.; Xiao, C.; Lu, L.-Q.; An, J.; Tan, F.; Li, B.-J.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2012**, *51*, 9137. (d) Cheng, H.-G.; Lu, L.-Q.; Wang, T.; Yang, Q.-Q.; Liu, X.-P.; Li, Y.; Deng, Q.-H.; Chen, J.-R.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2013**, *52*, 3250.

(12) See the Supporting Information for more details.

(13) (a) Wang, G.; Liu, X.; Huang, T.; Kuang, Y.-L.; Lin, L.; Feng, X. *Org. Lett.* **2013**, *15*, 76. (b) Singh, A.; Loomer, A. L.; Roth, G. P. *Org. Lett.* **2012**, *14*, 5266. (c) El-Sayed, M. A. A.; Abdel-Aziz, N. I.; Abdel-Aziz, A. A. M.; El-Azab, A. S.; ElTahir, K. E. H. *Bioorg. Med. Chem.* **2012**, *20*, 3306.